ObsEva (OBSV) Receives New Coverage from Analysts at BMO Capital Markets
Several other research analysts have also recently issued reports on OBSV. HC Wainwright set a $27.00 price objective on ObsEva and gave the stock a buy rating in a research note on Wednesday, August 16th. Leerink Swann restated an outperform rating and issued a $18.00 price objective on shares of ObsEva in a research note on Wednesday, August 16th. Zacks Investment Research cut ObsEva from a hold rating to a sell rating in a research note on Saturday, August 19th. Royal Bank Of Canada started coverage on ObsEva in a research note on Thursday, September 14th. They issued an outperform rating and a $22.00 price objective for the company. Finally, Credit Suisse Group started coverage on ObsEva in a research note on Monday, October 9th. They issued an outperform rating and a $16.00 price objective for the company. Seven investment analysts have rated the stock with a buy rating, The company has an average rating of Buy and a consensus price target of $19.00.
Shares of ObsEva (NASDAQ OBSV) opened at $9.49 on Monday. ObsEva has a twelve month low of $5.00 and a twelve month high of $14.69.
ObsEva (NASDAQ:OBSV) last announced its quarterly earnings data on Tuesday, November 14th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.01). ObsEva’s revenue was up NaN% compared to the same quarter last year. analysts anticipate that ObsEva will post -2.27 EPS for the current fiscal year.
Large investors have recently made changes to their positions in the company. Sphera Funds Management LTD. raised its position in ObsEva by 9.7% during the second quarter. Sphera Funds Management LTD. now owns 231,497 shares of the company’s stock valued at $1,979,000 after acquiring an additional 20,411 shares in the last quarter. VHCP Management II LLC purchased a new position in ObsEva during the second quarter valued at approximately $1,283,000. Sectoral Asset Management Inc raised its position in ObsEva by 181.9% during the second quarter. Sectoral Asset Management Inc now owns 212,831 shares of the company’s stock valued at $1,820,000 after acquiring an additional 137,331 shares in the last quarter. Abingworth LLP purchased a new position in ObsEva during the third quarter valued at approximately $3,480,000. Finally, Iguana Healthcare Management LLC raised its position in ObsEva by 66.7% during the third quarter. Iguana Healthcare Management LLC now owns 50,000 shares of the company’s stock valued at $407,000 after acquiring an additional 20,000 shares in the last quarter. Hedge funds and other institutional investors own 35.91% of the company’s stock.
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.
Receive News & Ratings for ObsEva SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva SA and related companies with Analyst Ratings Network's FREE daily email newsletter.